Active Ingredient History

NOW
  • Now
Pertuzumab, sold under the brand name Perjeta, is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$2382.0085

United States

$3703.8500 - $5042.8000
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( hyaluronidase (human recombinant) (hylenex), trastuzumab (herceptin), pertuzumab (perjeta) - other name: pertuzumab, trastuzumab, and hyaluronidase-zzxf )
2c4 antibody | moab 2c4 | monoclonal antibody 2c4 | omnitarg | omnitarg, 2c4 | omnitarg perjeta | perjeta | pertuzumab | rg-1273 | rhumab 2c4 | rhumab-2c4

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue